None
sg777 org
。
The tumult over, Bears players embracing the post-Matt Eberflus eraWarren Buffett's Berkshire hits near six month highPro Picks: Saquon Barkley and Derrick Henry go head-to-head in matchup of top 2 rushing leaders
Pulisic limps off in first half of Milan's 2-1 defeat
Maryland bullies Bucknell to secure third straight win
Report: Liverpool make €40m offer for Barca star with 35 goals & 48 assists; Arne Slot pushing for moveIt’s been a long road back to the highest levels of motorsport for Canadian driver Robert Wickens. Six years after he was paralyzed in a violent wreck, Wickens will again be behind the wheel against some of the best drivers in North America. Wickens, from Guelph, Ont., was named the newest driver for DXDT Racing earlier this week, moving the 35-year-old up to IMSA GTD competition for 2025, the highest class on the WeatherTech SportsCar Championship series. His promotion was made possible by a new hand control braking system created by Bosch Electronics, with help from GM Motorsports and Corvette Racing/Pratt Miller. “It’s not going to be easy but I wanted to get to the highest levels of motorsport again because, frankly, that’s where I was when I was injured,” said Wickens, who crashed at Pocono Raceway in 2018 during IndyCar’s ABC Supply 500. “But not only that, I want to prove to myself and other generations of people with disabilities that you can really do anything. “Maybe you’re having a hard time getting back to your place of work after a life-altering accident and — whatever your discipline, it doesn’t even have to be athletics — but I know it’s possible as long as you align yourself with a strong support system.” For Wickens, that’s been his wife Karli Wickens, his family and, in his professional life, organizations like Bosch and GM. Wickens’s crash left him with a thoracic spinal fracture, a neck fracture, tibia and fibula fractures to both legs, fractures in both hands, a fractured right forearm, a fractured elbow, four fractured ribs, a pulmonary contusion, and an indeterminate spinal injury that combined to make him a paraplegic. As he has slowly recovered some movement in his legs, Wickens has eased back into motor racing. He drove the parade lap of the 2019 Honda Indy Toronto, competed in the IndyCar iRacing Challenge during the early days of the COVID-19 pandemic, and then in January 2022 it was announced he would drive in the Michelin Pilot Challenge for Bryan Herta Autosport. He and co-driver Mark Wilkins won twice in the Michelin Pilot Challenge’s TCR category with three podiums in 2022. In 2023 the pairing didn’t win, but they reached the podium seven times to earn the TCR championship. All of Wickens’s post-accident cars have been fitted with hand controls. Those conventional systems rely on paddles around the steering wheel that activate pneumatics that then press the foot pedals. Hand controls like that are acceptable for regular road vehicles and even lower levels of motorsports but in the highest classes, like IMSA GTD where cars top out at more than 280 kilometres, the lag between the driver toggling the paddle and the car responding is unacceptably slow. That’s where the Bosch electronic system comes in, with the controls linked directly to the car’s braking system, removing the pneumatics as an intermediary. “When you hit the brakes to slow the car down for each corner that was always a big challenge for me where (with) the Bosch electronic system, the latency is milliseconds not tenths of a second,” said Wickens. “It’s basically as accurate as I would be if I was an able-bodied driver wanting to apply the brake. “Honestly, it’s just better in every facet imaginable. It’s just been a true blessing.” Advances in physical rehabilitation from spinal cord injuries as well as the ongoing development of vehicle technology has made Wickens’s return to competitive motorsport possible. “I’m very fortunate in the timing of my paralysis and my career,” Wickens said Wednesday from Tampa, Fla. “If this was even a decade ago we’d be having a very different conversation today.” The IMSA WeatherTech SportsCar Championship has four classes of vehicles: two sports prototype categories and two grand tourer classes. GTD is considered the highest of the four classes because each team must have at least a silver or bronze driver and more than one platinum-rated driver on a team is prohibited. “I want to win,” said Wickens. “I think the big thing for me on this journey back was I wanted to race again because I truly felt like I could still win. “I want to raise awareness for spinal cord injury and disability, not by just being a participant, but by being the guy. I want to win races, fight for podiums, win championships, every time I’m sitting in the car.” Wickens said he won’t just be a role model for people living with paralysis or other mobility disabilities, but the technology his car will employ in 2025 will likely become commercially available for use in road vehicles. “Motorsports and the automotive racing industry were founded to be a proving ground for everyday automotive vehicles,” he said. “From there you make road cars and road safety better. “Hopefully we can provide the technology and have regularly available components that can make any race car accessible for anyone that needs hand controls or any other form of disability.” This report by The Canadian Press was first published Nov. 27, 2024. Follow jchidleyhill.bsky.social on Bluesky.The confirmation battles over circuit court judges are generally much harder fights given their role in hearing appeals from district courts and often having the last word on legal matters.
Cash and cash equivalents at €13.9 million, as of September 30, 2024. Revenues of €1.3 million for the first nine months of 2024. On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million. Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 2024 2 and the receipt of the $10 million milestone payment under the amended license and collaboration agreement with CTTQ on November 18, 2024, the Company estimates that its cash, cash equivalents and deposits would enable it to finance its operations until the end of the second quarter of 2025 3 . Daix (France), New York City, (New York, United States), November 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today reported its cash position as of September 30, 2024 and its revenues for the first nine months of 2024. Cash and cash equivalents As of September 30, 2024, the Company’s cash and cash equivalents amounted to €13.9 million, compared to cash and cash equivalents at €26.9 million, short-term deposit 4 at €0.01 million, and long-term deposit 5 at €9.0 million as of December 31, 2023. Net cash used in operating activities amounted to (€64.2) million in the first nine months of 2024, compared to (€69.0) million for the same period in 2023 down by 7.0%. R&D expenses, mainly driven by the development of lanifibranor in MASH/NASH, for the first nine months of 2024 amounted to €71.7 million and were down 10.0% compared to the €79.6 million for the first nine months of 2023. The decrease in R&D expenses over the period is primarily due to the temporary voluntary pause in the recruitment of patients in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH/NASH (“NATiV3") following the Suspected Unexpected Serious Adverse Reaction (“SUSAR”) previously reported in the first quarter of 2024 and, to a lesser extent, due to the completion of the LEGEND Phase 2a combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes (“T2D”). R&D expenses have started to increase as expected in the second half of 2024 following the restart of patient recruitment in NATiV3, as well as the planned clinical development activities and related costs associated with the NATiV3 for the second half of 2024. Net cash generated from investing activities for the first nine months of 2024 amounted to €8.7 million, compared to (€3.5) million used for the same period in 2023. The change is mostly due to the variation in term deposits between both periods. Net cash generated from financing activities for the first nine months of 2024 amounted to €42.3 million compared to €30.2 million in the same period in 2023. The change is due to (i) the second tranche of €25 million drawn in January 2024 under the unsecured loan agreement granted by the European Investment Bank (“EIB”) with the issue of 3,144,654 warrants to the EIB, and (ii) the issuance on July 18, 2024, of royalty certificates (the “2024 Royalty Certificates”) subscribed by Samsara BioCapital, and existing shareholders BVF Partners, NEA, Sofinnova, and Yiheng, for an amount of €20.1 million. The 2024 Royalty Certificates give the holders thereof the right to an annual payment of royalties equal to 3% of the potential future net sales of lanifibranor, if any, in the United States, the European Union and the United Kingdom over a 14-year term from the date of their issuance 6 . Over the first nine months of 2024, the Company did not record any exchange rate effect on cash and cash equivalents, compared to a negative exchange rate effect of (€0.7) million for the same period in 2023, due to the evolution of the EUR/USD exchange rate. Financial information after closing the accounts On October 14, 2024, the Company announced a multi-tranche equity financing (the “Equity Raise”) of up to €348 million from both new and existing investors 2 . The Company closed the first part of the first tranche of the Equity Raise on October 17, 2024, and issued 34,600,507 new ordinary shares (the “T1 New Shares”) at a price of €1.35 per T1 New Share, and 35,399,481 prefunded warrants to purchase ordinary shares in the Company at an exercise price of €0.01 and a subscription price of €1.34 per new ordinary share and received €94.1 million in gross proceeds (net proceeds approximately €86.6 million). The second part of the first tranche and the second and third tranches of the Equity Raise remain subject to satisfaction of specified conditions, and in particular shareholder approval. On October 14, 2024, the Company also announced that it had amended its license and collaboration agreement with Chia Tai Tianqing Pharmaceutical (Guangzhou) CO., LTD. (“CTTQ”). Pursuant to the amendment, if the Company receives commitments from investors to subscribe to an equity raise, in two or three tranches, prior to December 31, 2024, for an aggregate amount of at least €180 million, CTTQ shall pay to the Company (i) $10 million within 30 days of settlement-delivery of the new shares and prefunded warrants in the first tranche of the Equity Raise, (ii) $10 million upon the completion of the second tranche of the Equity Raise and (iii) $10 million upon the publication by the Company of positive topline data announcing that any key primary endpoint or key secondary endpoint of the NATiV3 trial, with any dosage regimen tested in the trial, have been met. Under the terms of the Amendment, the total amount of milestone payments remains unchanged, while the royalties that Inventiva is eligible to receive have been reduced to the low single digits. The signing of the Equity Raise satisfied the condition of receiving commitments for an aggregate amount of at least €180 million and the closing of the first part of the first tranche of the Equity Raise satisfied the condition (i) above. Subsequently, on November 18, 2024, the Company received the first milestone payment of $10 million from CTTQ pursuant to this amendment. Considering its current cost structure and forecasted expenditures and including (i) the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the Equity Raise, and (ii) the first milestone of $10 million (gross proceeds) received under the amendment to the licensing agreement with CTTQ, the Company estimates that its cash, cash equivalents and deposits would enable it to finance its operations until the end of the second quarter of 2025 2 . The Company currently expects that the conditions for the closing of the second part of the first tranche of the Equity Raise will be satisfied in December 2024. Considering its current cost structure and forecasted expenditures, the Company estimates that the anticipated receipt of the proceeds (a gross amount of €21.4 million) from the second part of the first tranche of the Equity Raise announced on October 14, 2024 would be sufficient to extend the Company’s ability to finance its operations until middle of the third quarter of 2025. Revenues The Company’s revenues for the first nine months of 2024 amounted to €1.3 million, as compared to €1.9 million for the same period in 2023. *** Next key milestones expected Randomization of the last patient of the NATiV3 Phase 3 clinical trial evaluating lanifibranor in MASH/MASH – expected in the first half 2025 following the anticipated end of screening targeted for the end of the year 2024 Topline results of NATiV3 – expected in the second half of 2026 Upcoming shareholders meeting Shareholders general meeting – December 11, 2024 Upcoming investor conference participation 43 rd Annual J.P. Morgan Healthcare conference – January 13-16, 2025 – San Francisco 13th edition of Degroof Petercam’s virtual healthcare conference – January 21-24, 2025 Upcoming scientific conference participation MASH-TAG – January 9-12, 2025 – Park City Next financial results publication Full-Year 2024 Revenues and cash and cash equivalents : Thursday, February 13, 2025 (after U.S. market close) About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate and has a pipeline of two preclinical programs. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase 3 clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program. The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com Contacts Important Notice This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, unaudited financial information, forecasts and estimates with respect to Inventiva’s cash resources, the anticipated proceeds from the Equity Raise, completion and timing of the Equity Raise, the satisfaction in part or full of the conditions precedent to closing of the various tranches of the Equity Raise and the timing thereof, and the exercise by the investors of the warrants and pre-funded warrants issued in connection with the Equity Raise, Inventiva’s expectations regarding its collaboration agreement with CTTQ, including the achievement of specified milestones thereunder, forecasts and estimates with respect to Inventiva’s pre-clinical programs and clinical trials, including design, protocol, duration, timing, recruitment costs, screening and enrollment for those trials, including the ongoing NATiV3 Phase 3 clinical trial with lanifibranor in MASH/NASH, the clinical development of and regulatory plans and pathway for lanifibranor, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva’s product candidates, including lanifibranor, potential regulatory submissions, approvals and commercialization, Inventiva’s pipeline and preclinical and clinical development plans, the potential development of and regulatory pathway for odiparcil, future activities, expectations, plans, growth and prospects of Inventiva and its partners, and business and regulatory strategy, the potential commercialization of lanifibranor and achievement of any sales related thereto, potential payment of royalties and anticipated future performance. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”, “opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on enrollment or the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’s ability to obtain financing and to enter into potential transactions and Inventiva’s ability to satisfy in part or full the conditions precedent for additional tranches of the Equity Raise and the conditions with respect to CTTQ, and whether and to what extent the Warrants may be exercised and by which holders, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners’ clinical trials may not support Inventiva's and its partners’ product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’s clinical trials, Inventiva’s expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners’ control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s and its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva’s and its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2023 filed with the Autorité des Marchés Financiers on April 3, 2024, as amended on October 14, 2024, the Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2024, and the Half-Year Report for the six months ended June 30, 2024 on Form 6-K filed with the SEC on October 15, 2024 for other risks and uncertainties affecting Inventiva, including those described under the caption “Risk Factors”, and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. 1 Non-audited financial information. 2 Press release of October 14, 2024 3 This estimate is based on the Company’s current business plan and excludes any potential milestones payable to or by the Company and any additional expenditures related to the potential continued development of the odiparcil program or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based this estimate on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated. 4 Short-term deposits were included in the category “other current assets” in the IFRS consolidated statement of financial position and were considered by the Company as liquid and easily available. 5 The long-term deposit had a two year-term, was accessible prior to the expiration of the term with a notice period of 31 days and was considered as liquid by the Company. 6 Press release of July 18, 2024 Attachment Inventiva - PR - Q3 2024 CA Cash - EN - 11 21 2024 - Final
Supreme Court allows case to proceed against MetaGabelli Mario J buys $12,450 in Atlanta Braves holdings stock
In his new role, Dr. Greg Siourounis, who has played an instrumental role in the growth of Sui Foundation, will drive xMoney's expansion into providing access to better ways to move money through blockchain and its MiCA-compliant infrastructure xMoney's vision as the ultimate global, inter-bank, cross- crypto /fiat integrated payments platform will see it roll out a unified network for fiat and crypto payments backed by a native stablecoin , benefiting consumers, businesses, retailers and payment services VADUZ , Liechtenstein , Nov. 27, 2024 /PRNewswire/ -- xMoney Global , the global, inter-bank and cross crypto /fiat integrated payments platform has appointed award-winning economist Dr. Greg Siourounis as Co-Founder and CEO. The company is a Mastercard principal member, with strategic European licenses, such as e-Money and VASP. As the digital landscape continues to evolve with the coming MiCA regulation, xMoney Global intends to lead Europe into this new transformative EU regulated stablecoin era. Greg Siourounis will lead the integration of xMoney's advanced blockchain-enabled payments infrastructure with its upcoming stablecoin program. Stablecoins are a key driver of blockchain adoption in today's market, now surpassing Bitcoin , remittances, and PayPal in annual transaction volume. As such, xMoney's Global reputation positions it to bridge Web3 innovation with traditional finance, leading Europe into a new transformative EU regulated stablecoin era. Dr. Greg, who has played a pioneering role in the growth of Sui Foundation as its former Managing Director and who previously founded Everypay, will drive xMoney Global's next wave of growth. Beyond the standard reference of his academic work in 2024's Nobel Prize in Economics , Dr. Greg's career is also decorated with awards such as the 2005 Young Economist Award from The European Economic Association and the 2008 Austin Robinson Prize from The Royal Economic Society. His immediate target will be to focus on partnerships, regulatory alignment and market expansion, as xMoney Global looks to build a comprehensive payments platform that bridges legacy financial systems with the potential of decentralized finance. Commenting on his appointment, Dr. Greg Siourounis , CEO of xMoney Global , said, "As Europe prepares to embrace MiCA regulation, xMoney Global is positioned to redefine what compliant, secure, and seamless digital payments can be. Our goal is to deliver a solid and trusted ecosystem that combines the strengths of traditional finance with the flexibility of blockchain technology to create a future-ready payment experience." Beniamin Mincu , Co-founder of MultiversX , said, "xMoney Global's mission aligns perfectly with the vision of MultiversX to bring scalable and secure blockchain solutions to mainstream finance. This appointment marks a significant step toward building a more inclusive and resilient financial system." The launch of xMoney Global aims to offer a next-gen blockchain-as-a-service module backed by its native stablecoin , with key white-labeled services including acquiring, issuing, onramps/offramps and a sticky loyalty program, all backed by MultiversX's state-of-the-art sharding technology. Following the surge in crypto markets after Trump's pro- crypto Presidential win, xMoney will be ideally placed to accelerate real-world adoption as the easiest way for everyone (consumers, retail and e-commerce) to seamlessly access fiat and crypto currencies in an app, card or payment gateway. About xMoney Global: xMoney Global is a pioneering payments company and a Mastercard principal member with strategic European licenses, such as e-Money and VASP. xMoney Global aims to offer a seamless, secure, and future-focused payments ecosystem combining unique product focus, cutting-edge technology and strong compliance. Discover more at https://www.xmoney.com/ Media Contact: Essam Ali , essam@lunapr.io Luna PR Photo - https://mma.prnewswire.com/media/2568826/xMoney_Global.jpg View original content to download multimedia: https://www.prnewswire.com/news-releases/former-md-of-sui-foundation-greg-siourounis-joins-xmoney-global-as-co-founder-and-ceo-to-build-mica-regulated-stablecoin-platform-302317744.html SOURCE xMoney GlobalIn his new role, Dr. Greg Siourounis, who has played an instrumental role in the growth of Sui Foundation, will drive xMoney's expansion into providing access to better ways to move money through blockchain and its MiCA-compliant infrastructure xMoney's vision as the ultimate global, inter-bank, cross- crypto /fiat integrated payments platform will see it roll out a unified network for fiat and crypto payments backed by a native stablecoin , benefiting consumers, businesses, retailers and payment services VADUZ , Liechtenstein , Nov. 27, 2024 /PRNewswire/ -- xMoney Global , the global, inter-bank and cross crypto /fiat integrated payments platform has appointed award-winning economist Dr. Greg Siourounis as Co-Founder and CEO. The company is a Mastercard principal member, with strategic European licenses, such as e-Money and VASP. As the digital landscape continues to evolve with the coming MiCA regulation, xMoney Global intends to lead Europe into this new transformative EU regulated stablecoin era. Greg Siourounis will lead the integration of xMoney's advanced blockchain-enabled payments infrastructure with its upcoming stablecoin program. Stablecoins are a key driver of blockchain adoption in today's market, now surpassing Bitcoin , remittances, and PayPal in annual transaction volume. As such, xMoney's Global reputation positions it to bridge Web3 innovation with traditional finance, leading Europe into a new transformative EU regulated stablecoin era. Dr. Greg, who has played a pioneering role in the growth of Sui Foundation as its former Managing Director and who previously founded Everypay, will drive xMoney Global's next wave of growth. Beyond the standard reference of his academic work in 2024's Nobel Prize in Economics , Dr. Greg's career is also decorated with awards such as the 2005 Young Economist Award from The European Economic Association and the 2008 Austin Robinson Prize from The Royal Economic Society. His immediate target will be to focus on partnerships, regulatory alignment and market expansion, as xMoney Global looks to build a comprehensive payments platform that bridges legacy financial systems with the potential of decentralized finance. Commenting on his appointment, Dr. Greg Siourounis , CEO of xMoney Global , said, "As Europe prepares to embrace MiCA regulation, xMoney Global is positioned to redefine what compliant, secure, and seamless digital payments can be. Our goal is to deliver a solid and trusted ecosystem that combines the strengths of traditional finance with the flexibility of blockchain technology to create a future-ready payment experience." Beniamin Mincu , Co-founder of MultiversX , said, "xMoney Global's mission aligns perfectly with the vision of MultiversX to bring scalable and secure blockchain solutions to mainstream finance. This appointment marks a significant step toward building a more inclusive and resilient financial system." The launch of xMoney Global aims to offer a next-gen blockchain-as-a-service module backed by its native stablecoin , with key white-labeled services including acquiring, issuing, onramps/offramps and a sticky loyalty program, all backed by MultiversX's state-of-the-art sharding technology. Following the surge in crypto markets after Trump's pro- crypto Presidential win, xMoney will be ideally placed to accelerate real-world adoption as the easiest way for everyone (consumers, retail and e-commerce) to seamlessly access fiat and crypto currencies in an app, card or payment gateway. About xMoney Global: xMoney Global is a pioneering payments company and a Mastercard principal member with strategic European licenses, such as e-Money and VASP. xMoney Global aims to offer a seamless, secure, and future-focused payments ecosystem combining unique product focus, cutting-edge technology and strong compliance. Discover more at https://www.xmoney.com/ Media Contact: Essam Ali , [email protected] Luna PR Photo - https://mma.prnewswire.com/media/2568826/xMoney_Global.jpg SOURCE xMoney GlobalOphthalmic Packaging Market Worldwide Industry Analysis, Future Demand and Forecast till 2031
Becton Dickinson EVP David Shan sells $330,375 in stockB. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of DoorDash, Inc. ( NASDAQ:DASH – Free Report ) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 7,189 shares of the company’s stock, valued at approximately $1,026,000. Several other hedge funds also recently bought and sold shares of the company. Rakuten Securities Inc. grew its stake in DoorDash by 302.3% in the 3rd quarter. Rakuten Securities Inc. now owns 173 shares of the company’s stock worth $25,000 after buying an additional 130 shares in the last quarter. Meeder Asset Management Inc. grew its stake in DoorDash by 82.0% in the 2nd quarter. Meeder Asset Management Inc. now owns 293 shares of the company’s stock worth $32,000 after buying an additional 132 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of DoorDash in the 2nd quarter worth approximately $32,000. Versant Capital Management Inc lifted its holdings in shares of DoorDash by 340.8% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the company’s stock worth $36,000 after acquiring an additional 259 shares during the last quarter. Finally, Quest Partners LLC lifted its holdings in shares of DoorDash by 146.8% in the 2nd quarter. Quest Partners LLC now owns 343 shares of the company’s stock worth $37,000 after acquiring an additional 204 shares during the last quarter. Hedge funds and other institutional investors own 90.64% of the company’s stock. DoorDash Stock Performance Shares of DASH stock opened at $177.24 on Friday. DoorDash, Inc. has a one year low of $92.56 and a one year high of $178.16. The company’s 50-day moving average is $153.61 and its 200 day moving average is $128.96. The company has a market capitalization of $73.62 billion, a price-to-earnings ratio of -393.87, a price-to-earnings-growth ratio of 13.31 and a beta of 1.67. Analyst Ratings Changes DASH has been the subject of a number of recent research reports. Jefferies Financial Group boosted their price objective on shares of DoorDash from $155.00 to $180.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Needham & Company LLC boosted their price objective on shares of DoorDash from $145.00 to $180.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. JMP Securities boosted their price objective on shares of DoorDash from $160.00 to $190.00 and gave the stock a “market outperform” rating in a report on Thursday, October 31st. BTIG Research upgraded shares of DoorDash from a “neutral” rating to a “buy” rating and set a $155.00 price objective for the company in a report on Thursday, September 19th. Finally, Wells Fargo & Company boosted their price objective on shares of DoorDash from $127.00 to $142.00 and gave the stock an “equal weight” rating in a report on Friday, October 4th. Ten investment analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the stock. Based on data from MarketBeat.com, DoorDash has a consensus rating of “Moderate Buy” and an average price target of $164.03. Read Our Latest Stock Report on DoorDash Insider Activity at DoorDash In other DoorDash news, Director Stanley Tang sold 1,855 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $169.98, for a total transaction of $315,312.90. Following the transaction, the director now owns 35,413 shares in the company, valued at approximately $6,019,501.74. This represents a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Also, CFO Ravi Inukonda sold 7,000 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $127.86, for a total transaction of $895,020.00. Following the transaction, the chief financial officer now owns 396,152 shares in the company, valued at $50,651,994.72. This represents a 1.74 % decrease in their position. The disclosure for this sale can be found here . In the last ninety days, insiders have sold 547,753 shares of company stock valued at $84,544,996. 7.92% of the stock is owned by insiders. DoorDash Company Profile ( Free Report ) DoorDash, Inc, together with its subsidiaries, operates a commerce platform that connects merchants, consumers, and independent contractors in the United States and internationally. The company operates DoorDash Marketplace and Wolt Marketplace, which provide various services, such as customer acquisition, demand generation, order fulfillment, merchandising, payment processing, and customer support. Featured Stories Want to see what other hedge funds are holding DASH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DoorDash, Inc. ( NASDAQ:DASH – Free Report ). Receive News & Ratings for DoorDash Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DoorDash and related companies with MarketBeat.com's FREE daily email newsletter .
Global Banking, Financial Services, And Insurance BFSI Crisis Management Market To Reach $24.23 Billion By 2028
The Miami Dolphins (5-6) ring in the holidays against the Green Bay Packers (8-3) with a Thanksgiving Day game. Kickoff Thursday from Lambeau Field is set for 8:20 p.m. EST (NBC). Let's analyze BetMGM Sportsbook's NFL odds around the Dolphins vs. Packers odds , and make our expert NFL picks and predictions . The Phins have won 3 straight after a 34-15 win over the New England Patriots as 7.5-point favorites. QB Tua Tagovailoa is rounding into form as he threw for 317 yards and 4 TDs. WR Jaylen Waddle (8-144-1) and TE Jonnu Smith (9-87-1) balled out in the victory. The Packers have won 2 straight and 6 of 7 games after a 38-10 beatdown of the beat-up San Francisco 49ers. They were 6-point faves in that one. RB Josh Jacobs controlled the game with 26 carries for 106 yards and 3 TDs. QB Jordan Love didn't have to do a whole lot as he was 13-for-23 for 163 yards and 2 scores. Play our free daily Pick’em Challenge and win! Play now ! Dolphins at Packers odds Provided by BetMGM Sportsbook ; access USA TODAY Sports Scores and Sports Betting Odds hub for a full list of NFL odds . Lines last updated at Wednesday at 6:32 p.m. ET. WIN YOUR FANTASY FOOTBALL LEAGUE! The Huddle has been turning players like you into winners for over 25 years. This season, it's your turn. Custom fantasy football rankings, sleepers and tools are just a click away. Save 25% off the Internet's best-kept secret. Subscribe now ! Dolphins at Packers key injuries Dolphins Packers FOOTBALL NEVER STOPS Live games, analysis and more 7 days a week: Get ESPN+ Dolphins at Packers picks and predictions Prediction Packers 24, Dolphins 20 Moneyline It's slated to be 27 degrees for this game, and Miami is a warm-weather team that will likely flounder in the cold. However, -185 is too steep for me. JOSH JACOBS OVER 74.5 RUSHING YARDS (-110) is a no-brainer for me. He has hit this mark in 5 straight games, and the cold weather will give Green Bay the advantage to run some clock. Against the spread Go easy here, and I would consider paying to scale it back to -2.5 (-150), but I will take the PACKERS -3.5 (-105) . The Pack have gone 1-4 ATS over the last 5 games, and the Dolphins' offense has looked good. But this weather is a different animal. Over/Under The Packers are 4-5-1 O/U in the last 10 games, and the Dolphins are 5-5. These teams last met in 2022 in Miami, and the Under hit with the Pack winning 26-20. The last time Miami was in Lambeau was 2018 and it was a 31-12 Packers victory with an Under cash. I like the UNDER 47.5 (-105) . Want to play some games of your own? Play for free at the best social casinos and enjoy lots of slots, blackjack, video poker, roulette and more. You can even earn real prizes! For more sports betting picks and tips , check out SportsbookWire.com and BetFTW . Follow Ryan Dodson on Twitter/X . Follow SportsbookWire on Twitter/X and like us on Facebook . Access more NFL coverage: BetFTW | TheHuddle Fantasy Football | BearsWire | BengalsWire | BillsWire | BroncosWire | BrownsWire | BucsWire | CardsWire | ChargersWire | ChiefsWire | ColtsWire | CommandersWire | CowboysWire | DolphinsWire | EaglesWire | FalconsWire | GiantsWire | JaguarsWire | JetsWire | LionsWire | NinersWire | PackersWire | PanthersWire | PatriotsWire | RaidersWire | RamsWire | RavensWire | SaintsWire | SeahawksWire | SteelersWire | TexansWire | TitansWire | VikingsWire | DraftWire | TouchdownWire | ListWire More NFL Picks and Predictions! Fantasy football rankings (PPR scoring) and cheat sheets: Week 13 New York Giants at Dallas Cowboys odds, picks and predictions Best NFL underdog picks and predictions for Week 13Ministers told ‘incompetence’ at Met Office led to underestimation of Storm Bert
Peoples Bancorp of North Carolina director James Abernethy sells $15,950 in stockPassive income can help get you on the road to financial freedom. As you grow your passive income sources, you'll become less reliant on your job to support your lifestyle. Investing in real estate investment trusts ( REITs ) can be a great way to start building your passive income. Several REITs offer high-yielding dividends that they pay monthly, making them ideally suited for generating recurring income . For example, $5,000 invested across a trio of monthly dividend REITs could produce nearly $275 of dividend income per year (almost $23 each month): Monthly Dividend Stock Investment Current Yield Annual Dividend Income EPR Properties ( EPR 0.49% ) $1,666.67 7.65% $127.50 Stag Industrial ( STAG 1.00% ) $1,666.67 4.07% $67.83 Gladstone Land ( LAND 1.95% ) $1,666.67 4.73% $78.83 Total $5,000.00 5.48% $274.17 Data source: Google Finance. Table by author. That income stream should grow as these REITs increase their dividends. Your ticket to a lucrative monthly income stream EPR Properties is a specialty REIT focused on owning experiential properties like movie theaters, eat-and-play venues, and attractions. The REIT leases these properties to tenants that operate the experiences. It typically gets paid a stable base rental rate and , in some cases, gets a cut of the property's revenue. The company is on track to generate $4.80-$4.92 per share of funds from operations ( FFO ) as adjusted this year . That's plenty of cash flow to cover its monthly dividend payment of $0.285 per share ($3.42 annualized). EPR Properties retains the excess cash to fund new income-generating experiential property investments. It will invest $225 million to $275 million into new properties this year, which includes development and redevelopment projects. The REIT expects new property investments to grow its FFO per share by around a 3% to 4% annual rate . That should enable it to increase its dividend by about a similar rate (it raised its payout by 3.6% this year). Multiple growth drivers Stag Industrial is an industrial REIT that owns warehouse and light manufacturing facilities. The company leases those properties to high-quality tenants under long-term contracts that escalate rents at a low-single-digit annual rate. The REIT currently pays out about 73% of its stable rental income via its monthly dividend. That enables it to retain about $100 million each year to fund new investments. Stag Industrial also has a very strong balance sheet, giving it additional cash to fund new income-generating industrial real estate investments. The company expects to invest $500 million to $700 million into acquiring additional properties this year. Demand for industrial real estate is robust these days due to the rising adoption of e-commerce and the onshoring of manufacturing. That's driving up rental rates for properties in the market. Stag Industrial is steadily capturing this market rent growth by signing new leases at higher market rates as legacy leases expire. The company has signed new and renewal leases at an average rental increase of about 30% this year compared to expiring rental rates. Rising rents (contractual and market) and new property additions are growing the REIT's FFO per share. That's enabling it to steadily raise its dividend, which it has done every year since it came public in 2011. Steady dividend growth Gladstone Land is a farmland REIT . It owns farms leased to farmers at either a fixed rate or participation rental rate, where it gets a portion of the annual crop revenue. The REIT routinely increases its monthly dividend (35 times over the last 39 quarters). The company grows its dividend by acquiring new farms. It also benefits from rent growth and rising crop income. For example, it recently renewed or amended eight leases of farms that grow annual row crops at an 11% higher rate compared to the prior lease rate. Gladstone Land has experienced some setbacks over the past year due to the impact of lower crop prices on some tenants. It has had to take back 20 farms that are either currently vacant or that it now directly operates. It has also had to renegotiate some other leases at lower initial rental rates in exchange for greater participation in future crop revenue. The company expects to work through these issues by the end of the year and should see higher revenue in the second half of 2025, when its farms harvest their crops. That should enable the REIT to continue growing its dividend in the future. Ideal passive income producers REITs are great passive income investments because they generate steady rental income that they distribute to investors. EPR Properties, Stag Industrial, and Gladstone Land pay attractive monthly dividends, making them ideal options for those seeking lots of recurring passive income.
NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Mercurity Fintech Holding Inc. (the “Company,” “we,” “us,” “our company,” or “MFH”) (Nasdaq: MFH), a digital fintech group powered by blockchain technology, today announced its unaudited financial results for the six months ended June 30, 2024. First Half 2024 Financial and Operating Highlights GAAP revenue - First half 2024 GAAP revenues of USD$517,177, compared to revenues of USD$246,242 in first half 2023, reflecting an increase of 110.03% in GAAP revenue and demonstrating the Company’s enhanced profitability and diversified revenue stream for the six months ended June 30, 2024. GAAP gross loss - First half 2024 GAAP gross loss of USD$276,444, compared to gross loss of USD$447,178 in first half 2023, reflecting a decrease of 38.18% in GAAP gross loss. GAAP net loss - First half 2024 GAAP net loss of USD$3,834,465, compared to net loss of USD$2,578,541 in first half 2023, reflecting an increase of 48.71% in GAAP net loss. For detailed financial results, please refer to the Company’s filing. About Mercurity Fintech Holding Inc. Mercurity Fintech Holding Inc. is a digital fintech company with subsidiaries specializing in distributed computing and digital consultation across North America and the Asia-Pacific region. Our focus is on delivering innovative financial solutions while adhering to principles of compliance, professionalism, and operational efficiency. Our aim is to contribute to the evolution of digital finance by providing secure and innovative financial services to individuals and businesses. And our dedication to compliance, professionalism, and operational excellence ensures that we remain a trusted partner in the rapidly transforming financial landscape. Cautionary Statement Regarding Forward Looking Statements We have made statements in this report that constitute forward-looking statements. Forward-looking statements involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “we believe,” “we intend,” “may,” “should,” “could” and similar expressions. These statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances or achievements expressed or implied by the forward-looking statements. These forward-looking statements include statements about: our business and operating strategies and plans for the development of existing and new businesses, ability to implement such strategies and plans and expected time; developments in, or changes to, laws, regulations, governmental policies, incentives, taxation and regulatory and policy environment affecting our operations and the cryptocurrency and blockchain industry; our future business development, financial condition and results of operations; expected changes in our revenues, costs or expenditures; general business, political, social and economic conditions in mainland China and the international markets where we base our operations. The ultimate correctness of these forward-looking statements depends upon a number of known and unknown risks and events. Many factors could cause our actual results to differ materially from those expressed or implied in our forward-looking statements. Consequently, you should not place undue reliance on these forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and, except as required by law; we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update this forward-looking information. Nonetheless, we reserve the right to make such updates from time to time by press release, periodic report or other method of public disclosure without the need for specific reference to this interim report. No such update shall be deemed to indicate that other statements not addressed by such update remain correct or create an obligation to provide any other updates. CONTACTS Mercurity Fintech Holding Inc. Hoi Yi Xian ir@mercurityfintech.com Tel: + 1 646 283 7120 International Elite Capital Inc. Vicky Cheung Tel: +1(646) 866-7928 Email: mfhfintech@iecapitalusa.com
President-elect Donald Trump’s announcement that on all goods imported from Canada and Mexico, and an extra 10% on all Chinese goods on top of existing tariffs, has all the hallmarks of a classic Trump policy proclamation. He , while in reality it’s a terrible idea that he may not even enact. And what he does plan to do may be even worse. This is an economic story with serious real-world consequences, few of them good. But it’s also a performance, full of bluff and bluster — and a preview of the corruption that will be a hallmark of his second term in office. During the campaign, Trump said he wanted to impose tariffs of 10%-20% on all imported goods, and up to 60% on goods coming in from China; this proposal is just the start. Were these tariffs actually put in place — and again, the jury is still out on whether Trump will actually follow through — they would be devastating to the American economy. In 2023, we just under $900 billion worth of goods from Mexico and Canada, everything from avocados to lumber to auto parts. Putting a 25% tariff on all of it would amount to a sales tax of $225 billion — or increased costs of about $1,800 per American . Trump’s proposal would also trash the United States-Mexico-Canada Agreement, the free-trade accord Trump himself signed in 2020, and inevitably produce retaliation from the affected countries; Mexican President Claudia Sheinbaum that if Trump imposes these tariffs, Mexico will respond in kind. We saw that in the first Trump administration as well: When he imposed tariffs on Chinese goods, China responded by cutting off imports of American agricultural commodities. American farmers who rely on exports had their livelihoods threatened, so the Trump administration paid them off. In the end, 92% of the revenues brought in by the tariffs — which were essentially paid by American taxpayers — of farmers, to the tune of over $60 billion. If the affected population had been people Trump didn’t want to help — let’s say, minority populations living in cities — he may have let them suffer (recall that he initially refused to until aides explained how many residents voted for him). But he was happy to have Americans subsidize a bailout for farmers, because rural voters are essential to his base. You can call this approach “transactional,” or you can call it corrupt. “To me, the world’s most beautiful word in the dictionary is tariffs. It’s my favorite word,” , and now he is promising tariffs much more comprehensive than those implemented during his first term. That experience gives us a guide to how his future tariffs will be deployed. As soon as tariffs were enacted in his first term, his administration was by lobbyists, who filed thousands of requests for special exemptions and carve-outs to allow their clients to import goods and parts without paying the tariffs. And who found favor with the Trump administration? According to , companies that had donated to Republican candidates were more likely to get their exemption requests approved; one of the researchers “a very effective spoils system.” While small businesses lacked the resources to file for exclusions, bigger corporations and their chief executives could expend the time and money necessary to claim carve-outs. Apple and its CEO, Tim Cook, offer an illustrative case study. Throughout Trump’s first term, Cook buttered Trump up with personal attention, something other CEOs who found Trump personally repugnant were more reluctant to do. As , Cook tailored a strategy to massage Trump’s ego over a series of meals and meetings in which he would explain how Apple’s interests dovetailed with Trump’s. “That’s why he’s a great executive, because he calls me and others don’t,” Trump would later say. The strategy paid off with tax breaks and changes to Trump’s tariff plan that kept the iPhone safe from price increases that would go into government coffers rather than Apple’s. In a second term, Trump won’t just be doling out favors; he’ll also deliver punishments. During the campaign he about how John Deere was planning to move jobs to Mexico, but likely changed its plans after he threatened the company with tariffs so high it wouldn’t be able to sell the equipment it made there in the U.S. The story may have been false, but the message was clear: Trump will not hesitate to single out specific companies with penalties (and ensuing abuse from his army of online trolls) if he doesn’t like what they’re doing. We’ve seen before how personal Trump’s view of the economy is: There are good companies and bad companies, within good industries and bad industries, and the determining factor is whether they treat him like the king he imagines himself to be. Firms looking at this history might reasonably decide that making good products isn’t enough to succeed; they also must win the goodwill of a petty and mercurial president, just as companies do in dictatorships around the world. And since everyone knows that Trump is not above a personal payoff, they might feel it wise to put money directly in his pocket. There are multiple ways to do so: They could book rooms at his resorts (as in his first term), or boost in the Trump Media & Technology Group with a large purchase of shares, or invest in his , or perhaps buy a few thousand or or . This president makes it easy to grease his palm. Trump believes that tariffs can do almost anything — force other countries to their knees, bring prosperity to the nation, even restore your sense of manly virility. Best of all, they can provide an avenue for him to reward those who please him, hurt those who fail to bend the knee, and maybe even use his office to make a few more bucks. As corrupt as Trump’s first term was, it could pale in comparison to the second.NAPLES, Fla. (AP) — Down by two shots with two holes to play, Jeeno Thitikul knew exactly what was needed to capture the biggest prize in women's golf history. And another eagle-birdie finish — for the second straight day — made it happen. Thitikul claimed the record-setting $4 million first-place check by winning the CME Group Tour Championship on Sunday. It's the biggest money prize in women’s golf history, bigger than even the winner’s shares in three of the four men’s major championships this year. Her plans for all that cash? “Definitely spend it,” Thitikul said. “That's an honest answer, for sure. Definitely going to spend it for a little while.” Thitikul shot a 7-under 65 on Sunday and finished the week at 22 under, one shot ahead of Angel Yin (66). Yin had a two-shot lead walking to the 17th tee, only to wind up settling for the $1 million runner-up check. Yin — who missed the start of the season after breaking her leg over the winter — hardly sounded defeated after finishing second and more than doubling her 2024 earnings in four days. “I’m pretty awesome. ... I’ve learned that I just need to believe my myself and that’s what I did," Yin said. Olympic gold medalist Lydia Ko (63) finished third at 17 under, her nine birdies coming in a 13-hole span. “I’m excited to be able to work hard this offseason and have another great 2025,” Ko said. The win and the massive check came down to the 18th hole, Thitikul and Yin tied at 21 under after a back-and-forth day atop the leaderboard — both knowing a mistake would likely come with a $3 million cost. They both hit the fairway on 18. Thitikul's approach was nearly perfect, stopping about 5 feet from the cup. Yin's response stopped maybe 15 feet away, giving Thitikul the edge as they walked up the fairway. Yin's birdie putt just missed. Thitikul's was dead center. And history was hers. She already had clinched a $1 million bonus this week through the Aon Risk-Reward Challenge, a competition based on how players score on a designated hole each week. In the end, it wound up as a whopping $5 million week for the 21-year-old from Thailand — and going 8 under over the four days on the Nos. 17 and 18 at Tiburon Golf Club made it happen. “All the hard work paid off,” Thitikul said. Yin and Thitikul were tied for the lead entering the final round at 15 under. It didn’t take long for Thitikul to jump in front, with birdies on two of the first three holes to grab a two-shot edge. Her lead vanished on the par-4 fourth; Yin made birdie, Thitikul bogey and just like that they were tied again. It seemed like Yin seized some sort of control on the par-3 16th. — about 25 feet — rolled in for a two-shot lead with two holes to play. But her second shot at the par-5 17th missed the green right, and the door was opened for Thitikul. The eagle-birdie finish Saturday left Thitikul tied for the lead. The eagle-birdie finish Sunday made Thitikul a winner like none other in women’s golf. “Actually, I don’t know what’s happened to me on 17 and 18,” Thitikul said. “Having eagle is more than I can ask for.” Ruoning Yin (68) was alone in fourth at 16 under, and LPGA player of the year Nelly Korda (66) finished at 15 under along with Narin An (68). Ayaka Furue finished at 13 under, good enough to give her the Vare Trophy as the LPGA’s season-long scoring champion over Haeran Ryu. Lexi Thompson — a 15-time winner as a pro who plans to step away from full-time golf — finished at 2 under. It’s not clear how often Thompson plans to play in 2025 and beyond; that said, she returns to Tiburon the week of Dec. 9 for the Grant Thornton Invitational, where she’ll team with Rickie Fowler in the event featuring PGA Tour and LPGA Tour players. “I’m not going anywhere, guys.” Thompson said. “I’ll be back in two weeks.” There were two players who said they were retiring after Sunday’s round: Marina Alex, who shot 66 to finish at 12 under, and Ally Ewing, who closed with a 68 to wrap up the week at 11 under. “I’m happy to have ended on my best,” said Alex, a bottle of sparkling wine in her right hand, a bouquet of flowers in the other. Added Ewing: “I’ve been at peace with my decision. It’s just so nice to be able to share the walk with my family this week.” AP golf: